Strategic partnerships OncoNano has active collaboration activity with major pharma players, including a January 2026 partnership with Gilead Sciences to evaluate the ON-BOARD encapsulation platform. This indicates openness to co-development and licensing discussions that sales teams can leverage to explore co-ventures or sponsored research opportunities.

Clinical-stage momentum The company is advancing a nanotechnology based oncology pipeline with recent preclinical presentations at AACR and ongoing engagement at major oncology events. This suggests opportunities to align with translational research teams, contract research organizations, and potential early-access deals as candidates move toward INDs.

Leadership growth New executive leadership and recently promoted President and Head of R&D, Kartik Krishnan, in 2023–2025 imply a strategic shift and potential for new business development priorities, making them receptive to value-proposition discussions around platform flexibility and scalable collaborations.

Financing and scale With funding at around $188M and revenue in the low tens of millions, OncoNano is positioned for growth investments. Sales teams can explore sponsored research, milestone-based partnerships, or equity-backed collaborations to fund pipeline expansion.

Platform-driven value The ON-BOARD polymeric micelle technology targets a range of payloads from small molecules to biologics by exploiting tumor acidity, signaling a versatile platform suitable for licensing or collaborations across diverse therapeutic areas and drug modalities.